Inimmune is a private, clinical-stage biotech developing disease-modifying immunotherapies based on innate immune system modulation. Its lead programs are two clinical-stage TLR agonists: INI-2004 for allergic rhinitis (Phase 2) and INI-4001 for oncology (Phase 1). The company also has a robust pre-clinical pipeline focused on novel adjuvants and innate immune agonists/antagonists, supported by strategic academic and industry collaborations. Inimmune is pre-revenue and positioned in the high-potential but competitive immunotherapy and vaccine adjuvant markets.
Discovery and development of small molecule agonists/antagonists targeting innate immune receptors (TLRs, STING, etc.) for therapeutics and next-generation vaccine adjuvants.
Funding History
3
Total raised:$62.5M
Grant$2.5MNational Institutes of Health
Series B$40MRiverVest Venture Partners
Series A$20MTwo River Group
Opportunities
INI-2004 addresses a large allergic rhinitis market with a potential disease-modifying mechanism, moving beyond symptom relief.
The adjuvant platform offers high-value partnership potential in vaccine development for influenza, opioids, and pertussis, leveraging the renewed focus on vaccinology post-pandemic.
INI-4001 targets the vast immuno-oncology market with a novel TLR7/8 mechanism that could synergize with existing checkpoint inhibitors.
Risk Factors
The company faces high clinical risk with its lead Phase 2 allergy and Phase 1 oncology programs.
As a private, pre-revenue firm, it carries significant funding and dilution risk.
It also operates in highly competitive therapeutic areas against large, well-resourced pharmaceutical companies.
Competitive Landscape
In allergic rhinitis, Inimmune competes with allergen immunotherapy (SLIT tablets) and large pharma's biologic therapies. In oncology TLR agonists, it faces competition from companies like Merck (TLR7/8) and others. The adjuvant space is dominated by GSK and other large vaccine players, though niche opportunities in novel vaccines exist.
